• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Emerging Intralesional Treatments for Plantar Warts: A Systematic Review
CONCLUSION: Intralesional vitamin D3, in particular, demonstrated promising results as a potential second- or even first-line agent although not accessible in the United States. Candida antigen and bleomycin are less effective than intralesional vitamin D3, but given their greater accessibility and superiority to cryotherapy, should continue to be considered for treating recalcitrant plantar warts. Moreover, the quadrivalent human papillomavirus (HPV) vaccine, showing success in case reports, warrants further attention for both the treatment and prevention of plantar warts. J Drugs Dermatol. 2022;21(12):1322-1329. doi:10.3...
Source: Journal of Drugs in Dermatology - December 5, 2022 Category: Dermatology Authors: Amylee Martin Akshitha Thatiparthi Niki Nourmohammadi Cristina Nguyen Calvin Sung Natasha Atanaskova Mesinkovska Source Type: research

Revisiting Handwashing - As It Is Absolutely Essential.
Authors: Litchman GL, Marson JW, Bhatia N, Berman B Abstract As the coronavirus pandemic continues into the second half of 2020, states across the US remain steadfast in their search to determine the safest methods of returning to normalcy. Without a readily available, effective COVID-19 vaccine, and as the numbers of infected individuals continues to climb, the best practices to ensure public safety are rooted in good personal hygiene and prevention of transmission of the novel coronavirus SARS-CoV-2. To that end, in addition to properly wearing adequate facial covering, individuals should properly wash their hand...
Source: Journal of Drugs in Dermatology - November 19, 2020 Category: Dermatology Tags: J Drugs Dermatol Source Type: research

Update in Herpes Zoster Prevention and the Role of Dermatologists
Authors: Feli KH, Ediale CE, McMichael AJ Abstract A recombinant vaccine (HZ/su) was approved in 2017 to prevent herpes zoster (HZ) infection and associated sequelae with greater efficacy and safety than its live precursor. Though dermatologists regularly encounter patients with HZ infection, recommendation of vaccination by dermatologists and other physicians has been minimal in past years. Overall patient awareness and utilization of the HZ vaccines has subsequently been low. While HZ/su touts several improvements over the live vaccine, dermatologists still face obstacles to vaccine recommendation and administrat...
Source: Journal of Drugs in Dermatology - January 27, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research